Metabolic modulators of the exercise response: Doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)

Journal of Physiology and Pharmacology

Volumn 65, Issue 4, 2014, Pages 469-476

  Pokrywka, A ^a   Cholbinski, P ^a   Kaliszewski, P ^a   Kowalczyk, K ^a,b   Konczak, D ^a   Zembron Lacny, Agnieszka ^c  

^a Institute of Sport National Research Institute   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF ZIELONA GÓRA   (Poland)

Author keywords

Adenosine monophosphate activated protein kinase; Anti doping; Peroxisome proliferator activated receptor; Peroxisome proliferator activated receptor coactivator 1 alpha; Physical performance; Sport

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RIBONUCLEOTIDE; THIAZOLE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DOPING; ENDURANCE; EXERCISE; HUMAN; PHYSIOLOGY;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; DOPING IN SPORTS; EXERCISE; HUMANS; PHYSICAL ENDURANCE; PPAR DELTA; RIBONUCLEOTIDES; THIAZOLES;

EID: 84906853694     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. http://ec.europa.eu/sport.
2. http://www.who.int/dietphysicalactivity.
3. http://www.cdc.gov.
4. Bronnum-Hansen H, Juel K, Davidsen M, Sorensen J. Impact of selected risk factors on expected lifetime without long-standing, limiting illness in Denmark. Prev Med 2007; 45: 49-53.
5. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARd agonists are exercise mimetics. Cell 2008; 134: 405-415.
6. Feng YZ, Nikolic N, Bakke SS, et al. PPARd activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference. Arch Physiol Biochem 2014; 120: 12-21.
7. Sui X, Xu Y, Yang J, et al. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS One 2014; 9: e97781.
8. Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol 2005; 56: 149-162.
9. Ahmadian M, Suh JM, Hah N, et al. PPARg signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19: 557-566.
10. Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol 2002; 16: 707-721.
11. Li L, Beauchamp MC, Renier G. Peroxisome proliferatoractivated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 2002; 165: 101-110.
12. Celinski K, Dworzanski T, Fornal R, et al. Comparison of anti-inflammatory properties of peroxisome proliferatoractivated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol 2013; 64: 587-595.
13. Green S. PPAR: a mediator of peroxisome proliferator action. Mutat Res 1995; 333: 101-109.
14. Wang L, Psilander N, Tonkonogi M, Ding S, Sahlin K. Similar expression of oxidative genes after interval and continuous exercise. Med Sci Sports Exerc 2009; 41: 2136-2144.
15. Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004; 2: 1532-1539.
16. Barre L, Richardson C, Hirshman MF, et al. Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation. Am J Physiol Endocrinol Metab J 2007; 292: E802-E811.
17. Warden SJ, Fuchs RK. Are "exercise pills" the answer to the growing problem of physical inactivity? Br J Sports Med 2008; 42: 862-863.
18. Hawley JA, Holloszy JO. Exercise: it's the real thing! Nutr Rev 2009; 67: 172-178.
19. Goodyear LJ. The exercise pill - too good to be true? N Engl J Med 2008; 359: 1842-1844.
20. Barish GD, Narkar VA, Evans RM. PPARd: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597.
21. Matsakas A, Narkar VA. Endurance exercise mimetics in skeletal muscle. Curr Sports Med Rep 2010; 9: 227-232.
22. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathways. J Biol Chem 2002; 277: 25226-25232.
23. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor PPARa activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARa, PPARg, and their combination. Diabetes 2005; 54: 3358-3370.
24. http://www.sec.gov
25. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925.
26. Buhl ES, Jessen N, Pold R, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002; 51: 2199-2206.
27. Iglesias MI, Ye JM, Frangioudakis G, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002; 51: 2886-2894.
28. Jose C, Hebert-Chatelain E, Bellance N, et al. AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta 2011; 1807: 707-718.
29. Lanner JT, Georgiou DK, Dagnino-Acosta A, et al. AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation. Nat Med 2012; 18: 244-251.
30. Liu F, Zhou W, Liu X, et al. AICAR induces cell death in LKB1-deficient NSCLC. Cancer Res 2013; 73 (Suppl. 8): 1975.
31. Pold R, Jensen LS, Jessen N, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005; 54: 928-934.
32. Al-Moujahed A, Nicolaou F, Brodowska K, et al. Uveal melanoma cells are inhibited by AICAR partially through activation of AMP-dependent kinase. Invest Ophthalmol Vis Sci 2014; 55: 4175-4185.
33. Montraveta A, Xargay-Torrent S, Lopez-Guerra M, et al. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in vivo and in vitro models of mantle cell lymphoma. Oncotarget 2014; 5: 726-739.
34. Sabina RL, Holmes EW, Becker MA. The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). Science 1984; 223: 1193-1195.
35. Frederich MO, Rourke MR, Furey NB, Jost JA. AMPactivated protein kinase (AMPK) in the rock crab, cancer irroratus: an early indicator of temperature stress. J Exp Biol 2009; 212: 722-730.
36. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy review gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
37. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ 2006; 30: 145-151.
38. Osler ME, Zierath JR. Adenosine 5'-monophosphateactivated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology 2008; 149: 935-941.
39. Rantzau C, Christopher M, Alford FP. Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism. J Appl Physiol 2008: 104: 363-370.
40. http://playtrue.wada-ama.org
41. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ. Rat carcinogenicity study with GW501516, a PPAR delta agonist. Toxicologist 2009; 108: 185.
42. Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE. Mouse carcinogenicity study with GW501516, a PPAR delta agonist. Toxicologist 2009; 108: 185.
43. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 2004; 10: 245-247.
44. http://www.clinicaltrials.gov
45. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-d agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol 2012; 32: 2289-2294.
46. Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 2011; 96: E1568-E1576.
47. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008; 57: 332-339.
48. Sprecher DL, Massien C, Pearce G, et al. Triglyceride: highdensity lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007; 27: 359-365.
49. Aschenbach WG, Hirshman MF, Fujii N, Sakamoto K, Howlett KF, Goodyear LJ. Effect of AICAR treatment on glycogen metabolism in skeletal muscle. Diabetes 2002; 51: 567-573.
50. http://www.wada-ama.org
51. Thevis M, Beuck S, Thomas A, et al. Doping control analysis of emerging drugs in human plasma-identification of GW501516, S-107, JTV-519, and S-40503. Rapid Commun Mass Spectrum 2009; 23: 1139-1146.
52. Benkimoun P. Police find range of drugs after trawling bins used by Tour de France cyclists. BMJ 2009; 339: b4201.
53. Thomas A, Vogel M, Piper T, et al. Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. Anal Bioanal Chem 2013; 405: 9703-9709.
54. Pokrywka A, Kaliszewski P, Majorczyk E, Zembron-Lacny A. Genes in sport and doping. Biol Sport 2013; 30: 155-161.
55. Thevis M, Moller I, Thomas A, et al. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem 2010; 396: 2479-2491.
56. Thevis M, Moller I, Beuck S, Schanzer W. Synthesis, mass spectrometric characterization, and analysis of the PPARd agonist GW1516 and its major human metabolites: targets in sports drug testing. Methods Mol Biol 2013; 952: 301-312.
57. Sobolevsky T, Dikunets M, Sukhanova I, Virus E, Rodchenkov G. Detection of PPARd agonists GW1516 and GW0742 and their metabolites in human urine. Drug Test Anal 2012; doi: 10.1002/dta.1413.
58. http://www.uci.ch/.
59. Collins M. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Drug Test Anal 2011; 3: 404-416.
60. Cholbinski P, Wicka M, Kowalczyk K, et al. Detection of b- methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS. Anal Bioanal Chem 2014; 406: 3681-3688.
61. Pawar RS, Grundel E, Fardin-Kia AR, Rader JI. Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LCMS/ MS methods. J Pharm Biomed Anal 2014; 88: 457-466.
62. Kazlauskas R. Designer steroids. Handb Exp Pharmacol 2010; 195: 155-185.
63. Parr MK, Pokrywka A, Kwiatkowska D, Schanzer W. Ingestion of designer supplements produced positive doping cases unexpected by the athletes. Biol Sport 2011; 28: 153-157.
64. Thevis M, Geyer H, Thomas A, Schanzer W. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal 2011; 3: 331-336.
65. Bovee TF, Blokland M, Kersten S, et al. Bioactivity screening and mass spectrometric confirmation for the detection of PPARd agonists that increase type 1 muscle fibres. Anal Bioanal Chem 2014; 406: 705-713.
66. Thomas A, Beuck S, Eichoff JC, et al. Quantification of urinary AICAR concentrations as a matter of doping control. Anal Bioanal Chem 2010; 396: 2899-2908.
67. Cawley A, Flenker U. The application of carbon isotope ratio mass spectrometry to doping control. J Mass Spectrom 2008; 43: 854-864.
68. Piper T, Emery C, Saugy M. Recent development in the use of isotope ratio mass spectrometry in sport drug testing. Anal Bioanal Chem 2011; 401: 433-447.
69. Piper T, Thomas A, Baume N, et al. Determination of 13C/12C ratios of endogenous urinary 5-aminoimidazole-4- carboxamide 1b-D-ribofuranoside (AICAR). Rapid Commun Mass Spectrom 2014; 28: 1194-1202.